Mental Health Daily

Lateral Habenula & Depression: The Anti-Reward Center (Mechanisms & Antidepressant Treatments)

by GLOOM

Depression is a complex and multifaceted disorder affecting millions worldwide. Emerging evidence suggests the lateral habenula, a small brain region, plays a crucial role in depression’s development and persistence. By influencing neurotransmitter systems and interacting with stress pathways, the lateral habenula’s dysfunction may lead to the classic symptoms of depression. Highlights: The lateral habenula is …

Polyphenols & Depression: Antidepressant Potential of Plant Compounds

by GLOOM

Depression, a prevalent and debilitating mental health condition, affects millions worldwide. Recent studies have shown an intriguing link between dietary polyphenols, naturally occurring compounds in plant-based foods, and depression outcomes. Highlights: Prevalence of Depression: More than 300 million people globally suffer from depression, marking it as a leading cause of disability. Role of Polyphenols: Polyphenols, …

Mitophagy & Depression: Mitochondrial Autophagy as an Antidepressant Target?

by GLOOM

Depression is a pervasive mental health issue with complex origins and often inadequate treatment options. Recent studies have suggested that mitophagy, the process of selective mitochondrial autophagy, plays a crucial role in the onset and progression of depression, offering new insights into its pathogenesis and potential treatments. Highlights: Major Depressive Disorder (MDD) affects millions globally, …

Trends in U.S. Medicaid Antidepressant Prescriptions: Newer Drugs & Higher Costs (2023 Analysis)

by GLOOM

The U.S. Medicaid program’s spending and prescribing patterns for antidepressants between 2017 and 2021 reveal a significant shift toward newer and costlier medications. Highlights: Rising Expenditure: Medicaid’s spending on antidepressants increased from approximately $1 billion in 2017 to $1.12 billion in 2021. Preference Shift: There’s been a significant shift from older antidepressants like TCAs and …

Effects of Pramipexole on Reward Learning: Possible Depression Treatment? (2023 Study)

by GLOOM

In a significant stride toward understanding and treating depression, a 2023 study meticulously investigates the effects of pramipexole, a dopamine D2-like agonist, on reward learning. By exploring its impact on healthy volunteers through rigorous behavioral and neural assessments, the research offers groundbreaking insights into how this drug (occasionally used in depression) could revolutionize therapeutic strategies …

Zembrin® (Sceletium tortuosum) for Anxiety & Depression: Testing Alkaloid-Specific Effects (2023 Study)

by GLOOM

Sceletium tortuosum (ST) Extract, known as Zembrin®, is a traditional South African remedy was recently evaluated for its nuanced effects on anxiety and depression through a unique study using zebrafish larvae. Highlights: Zebrafish Larvae as Model Organisms: A study used zebrafish larvae to observe Zembrin®’s anxiolytic & antidepressant-like effects, offering a detailed and dynamic understanding …

Alzheimer’s Disease, Microglia, & Environmental Risk Factors (2024 Evidence)

by GLOOM

Alzheimer’s disease, a debilitating neurodegenerative condition, is influenced significantly by a blend of genetic, environmental, and lifestyle factors. New research focuses on environmental risk factors and microglia (the brain’s immune cells) for Alzheimer’s development. Highlights: Alzheimer’s Disease and Microglia: Alzheimer’s is characterized by cognitive decline, and microglia play a crucial role in its pathogenesis, acting …